The design and synthesis of spiroketal structures and their chemical modification, leading to a collection of new small molecules for biological evaluation as orally-bioavailable lead compounds is described. Both [6,5]- and [6,6]-membered ring spiroketal units have been prepared in a stereochemically-varying fashion starting from commercially available (R)- or (S)-glycidol, in ten, eleven and twelve linear steps, in overall yields of 45, 40 and 20%, respectively. Further elaboration according to Lipinski's guidelines has given a collection of structurally-diverse, new spiroketal derivatives in high yields and with high purity.
描述了一种设计和合成螺
缩酮结构及其
化学修饰的方法,最终获得一系列新的、可用于
生物评估的、具有口服
生物利用度潜力的先导化合物小分子。通过从市售的(R)-或(S)-
缩水甘油醇出发,在十步、十一 步和十二步线性步骤中,分别以45%、40%和20%的总产率,制备了立体
化学多样化的、含有[6,5]-和[6,6]-环成员的螺
缩酮单元。根据Lipinski规则进一步精细化工,得到了高产率、高纯度的、结构多样的新型螺
缩酮衍
生物。